×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ABBV – abbvie inc. (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ABBV
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/3
04:54 pm
abbv
AbbVie Inc. (ABBV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript [Seeking Alpha]
Low
Report
AbbVie Inc. (ABBV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript [Seeking Alpha]
12/2
09:36 am
abbv
AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers [Yahoo! Finance]
Low
Report
AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers [Yahoo! Finance]
12/2
08:15 am
abbv
AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
Low
Report
AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
12/1
06:01 am
abbv
AbbVie: Increased Outlook For 2025 And Expansions Merit Continued "Strong Buy" Rating [Seeking Alpha]
Low
Report
AbbVie: Increased Outlook For 2025 And Expansions Merit Continued "Strong Buy" Rating [Seeking Alpha]
12/1
04:00 am
abbv
AbbVie to Present Phase 3 ECLIPSE Data Demonstrating Atogepant (AQUIPTA®) Superiority Over Placebo in Achieving Pain Freedom for the Acute Treatment of Migraine at the 19th European Headache Congress
Low
Report
AbbVie to Present Phase 3 ECLIPSE Data Demonstrating Atogepant (AQUIPTA®) Superiority Over Placebo in Achieving Pain Freedom for the Acute Treatment of Migraine at the 19th European Headache Congress
11/30
09:29 am
abbv
AbbVie (NYSE:ABBV) Will Pay A Larger Dividend Than Last Year At $1.73 [Yahoo! Finance]
Low
Report
AbbVie (NYSE:ABBV) Will Pay A Larger Dividend Than Last Year At $1.73 [Yahoo! Finance]
11/30
03:33 am
abbv
AbbVie (NYSE:ABBV) was downgraded by analysts at Wall Street Zen fro
Low
Report
AbbVie (NYSE:ABBV) was downgraded by analysts at Wall Street Zen fro
11/28
07:01 am
abbv
SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance
Low
Report
SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/20
10:34 am
abbv
Form F-6 POS ABB LTD Filed by: Deutsche Bank Trust Co Americas/ ADR Group
Low
Report
Form F-6 POS ABB LTD Filed by: Deutsche Bank Trust Co Americas/ ADR Group
11/4
02:06 pm
abbv
Form 10-Q AbbVie Inc. For: Sep 30
Low
Report
Form 10-Q AbbVie Inc. For: Sep 30
10/31
07:52 am
abbv
Form 8-K AbbVie Inc. For: Oct 31
Medium
Report
Form 8-K AbbVie Inc. For: Oct 31
10/3
04:09 pm
abbv
Form 8-K AbbVie Inc. For: Oct 03
Low
Report
Form 8-K AbbVie Inc. For: Oct 03
10/2
05:01 pm
abbv
Form 4 AbbVie Inc. For: Sep 30 Filed by: Quaggin Susan E
Low
Report
Form 4 AbbVie Inc. For: Sep 30 Filed by: Quaggin Susan E
10/2
05:00 pm
abbv
Form 4 AbbVie Inc. For: Sep 30 Filed by: RAPP EDWARD J
Low
Report
Form 4 AbbVie Inc. For: Sep 30 Filed by: RAPP EDWARD J
10/2
05:00 pm
abbv
Form 4 AbbVie Inc. For: Sep 30 Filed by: Alpern Robert J
Low
Report
Form 4 AbbVie Inc. For: Sep 30 Filed by: Alpern Robert J
9/11
07:31 am
abbv
Form 8-K AbbVie Inc. For: Sep 11
Medium
Report
Form 8-K AbbVie Inc. For: Sep 11
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/26
Form PX14A6G AbbVie Inc. Filed by: United Church Funds, Inc.
9.7%
3/3 Form 4 AbbVie Inc. For: Feb 28 Filed by: Schumacher Laura J 4.8%
3/19 Israel OKs use of generic AbbVie drug to treat coronavirus despite patent [Reuters (UK)] 4.7%
2/7 Q4/2019 12/31/2019 EPS 2.210 ZacksConsensus 2.200 ActVsEst 0.010 - Beat 4.6%
3/23 Abbvie: Buy The Coronavirus Dip For These 3 Reasons [Seeking Alpha] 4.5%
6/27 AbbVie: $63 Billion Allergan Acquisition Just What The Doctor Ordered [Seeking Alpha] 3.7%
6/25 AbbVie Inc. (ABBV) CEO Rick Gonzalez on Acquisition of Allergan Conference Call (Transcript) [Seeking Alpha] 3.6%
11/8 AbbVie Submits Supplemental New Drug Application to U.S. FDA For IMBRUVICA® (ibrutinib) in Combination with Rituximab for the Treatment of Previously Untreated, Younger Adults with Chronic Lymphocytic Leukemia 3.6%
8/16 Form 4 AbbVie Inc. For: Aug 14 Filed by: Gosebruch Henry O 3.3%
6/26 AbbVie Inc (NYSE: ABBV) had its "hold" rating re-affirmed by analysts at Citigroup Inc. 3.2%
3/3 Form 4 AbbVie Inc. For: Feb 28 Filed by: Schumacher Laura J 4.8%
3/19 Israel OKs use of generic AbbVie drug to treat coronavirus despite patent [Reuters (UK)] 4.7%
2/7 Q4/2019 12/31/2019 EPS 2.210 ZacksConsensus 2.200 ActVsEst 0.010 - Beat 4.6%
3/23 Abbvie: Buy The Coronavirus Dip For These 3 Reasons [Seeking Alpha] 4.5%
6/27 AbbVie: $63 Billion Allergan Acquisition Just What The Doctor Ordered [Seeking Alpha] 3.7%
6/25 AbbVie Inc. (ABBV) CEO Rick Gonzalez on Acquisition of Allergan Conference Call (Transcript) [Seeking Alpha] 3.6%
11/8 AbbVie Submits Supplemental New Drug Application to U.S. FDA For IMBRUVICA® (ibrutinib) in Combination with Rituximab for the Treatment of Previously Untreated, Younger Adults with Chronic Lymphocytic Leukemia 3.6%
8/16 Form 4 AbbVie Inc. For: Aug 14 Filed by: Gosebruch Henry O 3.3%
6/26 AbbVie Inc (NYSE: ABBV) had its "hold" rating re-affirmed by analysts at Citigroup Inc. 3.2%
TOP News Decliners
6/25
AbbVie nears deal to buy Allergan for more than $60 bln - WSJ [Reuters]
-11.8%
3/20 Form 4 AbbVie Inc. For: Mar 18 Filed by: Durkin Brian L -6.5%
3/12 AbbVie Receives European Commission Approval of VENCLYXTO® Combination Regimen for Patients with Previously-Untreated Chronic Lymphocytic Leukemia -4.1%
2/24 Form 4 AbbVie Inc. For: Feb 20 Filed by: Durkin Brian L -3.9%
10/1 Lanny's October Dividend Stock Watch List [Seeking Alpha] -3.6%
3/10 Generic anti-malarial may treat COVID-19 - Raymond James [Seeking Alpha] -3.0%
2/27 AbbVie Inc (NYSE: ABBV) is now covered by analysts at Barclays PLC. They set an "equal weight" rating on the stock. -2.9%
3/17 AbbVie and Allergan Sign Consent Decree Agreement with Federal Trade Commission Staff on Pending Transaction -2.7%
4/7 Form PX14A6G AbbVie Inc. Filed by: ZEVIN ASSET MANAGEMENT LLC -2.6%
2/12 Results from Chinese drug trials for coronavirus due in weeks: expert [Reuters (UK)] -2.6%
3/20 Form 4 AbbVie Inc. For: Mar 18 Filed by: Durkin Brian L -6.5%
3/12 AbbVie Receives European Commission Approval of VENCLYXTO® Combination Regimen for Patients with Previously-Untreated Chronic Lymphocytic Leukemia -4.1%
2/24 Form 4 AbbVie Inc. For: Feb 20 Filed by: Durkin Brian L -3.9%
10/1 Lanny's October Dividend Stock Watch List [Seeking Alpha] -3.6%
3/10 Generic anti-malarial may treat COVID-19 - Raymond James [Seeking Alpha] -3.0%
2/27 AbbVie Inc (NYSE: ABBV) is now covered by analysts at Barclays PLC. They set an "equal weight" rating on the stock. -2.9%
3/17 AbbVie and Allergan Sign Consent Decree Agreement with Federal Trade Commission Staff on Pending Transaction -2.7%
4/7 Form PX14A6G AbbVie Inc. Filed by: ZEVIN ASSET MANAGEMENT LLC -2.6%
2/12 Results from Chinese drug trials for coronavirus due in weeks: expert [Reuters (UK)] -2.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: